bioRxiv Science⌕ Search

Biology subjects

Riffault, S.

Publications and source records attributed to Riffault, S..

4 recordsLinked to original sources

Early-Life Commensal Lung Bacteria Shape Immune Responses and RSV Susceptibility in Neonatal Mice

The lung mucosa during the neonatal period and early infancy is especially susceptible to respiratory syncytial virus (RSV) infection. Respiratory disease severity is strongly influenced by the age at first exposure, which may also affect the trajectory of airway function. Early life represents a critical window for lung development and initial microbiota colonization, both of which shape mucosal immune responses to RSV. The contribution of early lung-colonizing bacterial strains to the establishment of the lung microbiota and susceptibility to RSV infection in neonatal mice remains poorly characterized. In the present study, we showed that early-life primo-colonizing bacterial strains in the mouse lung differentially induce innate immune responses and influence RSV susceptibility in ex vivo models using lung explants and alveolar macrophages (AMs). We identified a specific bacterial strain (strain 17) whose prior exposure enhances type I interferon (IFN-I) responses in AMs upon RSV infection and reduces viral replication both ex vivo and in vivo in lung tissues. Intranasal administration of this strain during early life prevented the development of immunopathological responses upon RSV reinfection in adult mice. Finally, using a translational human airway epithelium model, we demonstrated that pre-exposure to strain 17 restricts RSV spread without cytotoxicity, likely via enhanced {beta}-defensin 2 production. These findings highlight the potential of early-life microbiota modulation as a promising intervention for preventing RSV disease and its long-term respiratory consequences. Author summaryRespiratory syncytial virus (RSV) is a major cause of severe respiratory infections in newborns and infants, a period during which the lungs and immune system are still maturing. Simultaneously, the respiratory tract undergoes its first microbial colonization by so-called primo-colonizing bacteria -- the first bacterial species to establish themselves on neonatal lower respiratory mucosal surfaces. These early microbial pioneers may play an unsuspected role in shaping how the immature immune system responds to viral threats. In this study, we investigated whether these early lung-colonizing strains influence RSV susceptibility. Using neonatal mouse models, lung explants, and alveolar macrophages, we found that distinct bacterial strains trigger markedly different innate immune responses. Prior exposure to one strain in particular, strain 17, was associated with enhanced type I interferon responses, reduced viral replication, and protection against harmful inflammation upon RSV reinfection later in life. In a human airway epithelium model, pre-exposure to strain 17 also restricted RSV spread without tissue damage, potentially through increased {beta}-defensin 2 production. These findings provide proof-of-concept that the bacterial strains establishing in the neonatal lung can influence future immune reactivity and antiviral responses, and suggest that early-life respiratory microbiota modulation could represent a promising strategy to prevent severe RSV disease.

immunology↗

The microbiota plays a critical role in the reactivity of lung immune components to innate ligands

The microbiota contributes to shaping efficient and safe immune defenses in the gut. However, little is known about the role of the microbiota in the education of pulmonary innate immune responses. Here, we tested whether the endogenous microbiota can modulate reactivity of pulmonary tissue to pathogen stimuli by comparing the response of specific pathogen-free (SPF) and germ-free (GF) mice. Using SPF and GF mice intranasally exposed to lipopolysaccharide (LPS), a component of Gram-negative bacteria, we observed earlier and greater inflammation in the pulmonary compartment of GF mice than that of SPF mice. Toll-like receptor 4 (TLR4) was more abundantly expressed in the lungs of GF mice than those of SPF mice at steady state, which could predispose the innate immunity of GF mice to strongly react to environmental stimuli. Lung explants were stimulated with different TLR agonists or infected with the human airways pathogen, respiratory syncytial virus (RSV), resulting in greater inflammation under almost all conditions for the GF explants. Finally, alveolar macrophages (AM) from GF mice presented a higher innate immune response upon RSV infection than those of SPF mice. Overall, these data suggest that the presence of microbiota in SPF mice induced a process of innate immune tolerance in the lungs by a mechanism which remains to be elucidated. Our study represents a step forward to establishing the link between the microbiota and the immune reactivity of the lungs. Plain Language summaryMicrobiota represents an important partner of immunologic system at the interface between immune cells and epithelium. It is well known, notably in the gut, that the microbiota contributes in shaping efficient and safe defenses. However, little is known about the role of the microbiota in the education of pulmonary innate immune responses. In this study, we postulate that endogenous microbiota could dampen an excessive reactivity of pulmonary tissue to external stimuli. Thus, we sought to study the innate immune reaction switched on by viral or bacterial ligands in respiratory tract cells coming from mice with or without microbiota (germ-free condition, GF). Altogether, our results show a higher inflammatory reaction in GF condition. This study represents a step forward to better establish the link between the microbiota and the reactivity of the lung tissue. Not only these data demonstrate that the microbiota educates the pulmonary innate immune system, but also contributes the emerging concept of using respiratory commensal bacteria as potential next-generation probiotics to prevent susceptibility to respiratory diseases.

immunology↗

Trivalent cocktail of de novo designed immunogens enables the robust induction and focusing of functional antibodies in vivo

De novo protein design has been successful in expanding the natural protein repertoire. However, most de novo proteins lack biological function, presenting a major methodological challenge. In vaccinology, the induction of precise antibody responses remains a cornerstone for next-generation vaccines. Here, we present a novel protein design algorithm, termed TopoBuilder, with which we engineered epitope-focused immunogens displaying complex structural motifs. Both in mice and non-human primates, cocktails of three de novo designed immunogens induced robust neutralizing responses against the respiratory syncytial virus. Furthermore, the immunogens refocused pre-existing antibody responses towards defined neutralization epitopes. Overall, our de novo design approach opens the possibility of targeting specific epitopes for vaccine and therapeutic antibody development, and more generally will be applicable to design de novo proteins displaying complex functional motifs.

bioengineering↗

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen

Throughout the last decades, vaccination has been key to prevent and eradicate infectious diseases. However, many pathogens (e.g. respiratory syncytial virus (RSV), influenza, dengue and others) have resisted vaccine development efforts, largely due to the failure to induce potent antibody responses targeting conserved epitopes. Deep profiling of human B-cells often reveals potent neutralizing antibodies that emerge from natural infection, but these specificities are generally subdominant (i.e., are present in low titers). A major challenge for next-generation vaccines is to overcome established immunodominance hierarchies and focus antibody responses on crucial neutralization epitopes. Here, we show that a computationally designed epitope-focused immunogen presenting a single RSV neutralization epitope elicits superior epitope-specific responses compared to the viral fusion protein. In addition, the epitope-focused immunogen efficiently boosts antibodies targeting the Palivizumab epitope, resulting in enhanced neutralization. Overall, we show that epitope-focused immunogens can boost subdominant neutralizing antibody responses in vivo and reshape established antibody hierarchies.

immunology↗